Rolf Hoffmann - Genmab AS Director
Director
Mr. Rolf K. Hoffmann has served as Independent Member of the Board of Directors of Genmab AS since March 28, 2017. He is Member of the Compensation Committee and the Scientific Committee of the Company. He has international management experience with expertise in creating and optimizing commercial opportunities in global markets, as well as additional expertise in PL management, governance and Corporationrationrate Integrity Agreement Management, compliance and organizational efficiency. He has over 20 years of experience in the international pharmaceutical and biotechnology industries at Eli Lilly and Amgen. He serves as Adjunct Professor Strategy and Entrepreneurship University of North Carolina Business School. He is also Member of the Board of Directors of EUSA Pharma, Inc and Trigemina, Inc., as well as Chairman of Biotest AG. Previously, he held Board Positions at SwissAmerican Chamber of Commerce, Council of Americas, International School of Zug and Luzern, University of North Carolina at Chapel Hill, International Advisory Board. since 2017.
Age | 57 |
Tenure | 7 years |
Phone | 45 70 20 27 28 |
Web | http://www.genmab.com |
Genmab AS Management Efficiency
The company has return on total asset (ROA) of 8.3 % which means that it generated a profit of $8.3 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 18.38 %, meaning that it generated $18.38 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Ron Kenedi | Westrock Coffee | 66 | |
Xiaoguang Wu | 51Talk Online Education | 45 | |
James Mastrian | Biglari Holdings | 76 | |
Pradeep Jotwani | Acco Brands | 66 | |
Scott Ford | Westrock Coffee | 61 | |
Kenneth Cooper | Biglari Holdings | 75 | |
Hans Norkus | Acco Brands | 73 | |
Scott Sandell | Coursera | 56 | |
Ruth Person | Biglari Holdings | 74 | |
Xing Liu | 51Talk Online Education | 47 | |
William Johnson | Biglari Holdings | 71 | |
Graciela Monteagudo | Acco Brands | 54 | |
Edward Roffman | Westrock Coffee | 64 | |
Robert Jenkins | Acco Brands | 72 | |
Gary Effren | Westrock Coffee | 56 | |
Mark Rajkowski | Acco Brands | 59 | |
Margaret Randazzo | Westrock Coffee | 46 | |
Ronald Lombardi | Acco Brands | 57 | |
James Buzzard | Acco Brands | 65 | |
Thomas Kroeger | Acco Brands | 72 | |
Carmen Chang | Coursera | 73 |
Management Performance
Return On Equity | 18.38 | |||
Return On Asset | 8.3 |
Genmab AS Leadership Team
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
Birgitte Stephensen, Senior Vice President IPR and Legal | ||
Daniel Bruno, Director, Employee Representative | ||
Peter Kristensen, Director, Employee Representative | ||
Nedjad Losic, Director, Employee Representative | ||
David Eatwell, CFO and Executive VP | ||
Paolo Paoletti, Director | ||
Michael Bauer, Senior Vice President Clinical Development | ||
Anthony Pagano, Senior Vice President Global Finance | ||
Martine Vugt, Senior Vice President Strategic Initiatives | ||
Andrew Carlsen, Senior Director, Investor Relations | ||
Paul Parren, Sr. VP and Scientific Director | ||
Tom Vink, Director, Employee Representative | ||
Rick Hibbert, Director, Employee Representative | ||
Pernille Erenbjerg, Director | ||
Mats Pettersson, Chairman of the Board | ||
Marisol Peron, Corporate Vice President Communications and Investor Relations | ||
Rolf Hoffman, Independent Director | ||
Rachel Gravesen, Senior Vice President Investor Relations and Communications | ||
Burton Malkiel, Independent Director | ||
Deirdre Connelly, Director | ||
Judith Klimovsky, Executive Vice President Chief Development Officer | ||
Tahamtan Ahmadi, Senior Vice President Oncology and Translational Medicine | ||
Anders Pedersen, Deputy Chairman of the Board | ||
Rolf Hoffmann, Director | ||
Jan Winkel, President and CEO |
Genmab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 18.38 | |||
Return On Asset | 8.3 | |||
Profit Margin | 45.85 % | |||
Current Valuation | 11.19 B | |||
Shares Outstanding | 615.13 M | |||
Shares Owned By Institutions | 0.06 % | |||
Price To Earning | 52.09 X | |||
Price To Book | 10.02 X | |||
Price To Sales | 22.59 X | |||
Revenue | 438.84 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Genmab Pink Sheet
If you are still planning to invest in Genmab AS check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genmab AS's history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |